Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 5/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28723840 | 0.84 | GPR35 (0.47) | SCN10AJAK2JAK1GPR35KCNH2 | |
| SCHEMBL19775942 | 0.83 | KCNH2 (0.43) | SCN10AJAK2JAK1GPR35KCNH2 | |
| SCHEMBL9413738 | 0.81 | PEPD (0.46) | CYP11B2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL27819815 | 0.80 | KCNH2 (0.42) | SCN10AGPR35KCNH2GRM5MALT1 | |
| SCHEMBL31129266 | 0.80 | KCNH2 (0.42) | SCN10AGPR35KCNH2GRM5MALT1 | |
| SCHEMBL8237778 | 0.79 | KCNH2 (0.46) | SCN10AKCNH2GRM5MALT1ALDH1A1 | |
| SCHEMBL1483915 | 0.79 | KCNH2 (0.48) | SCN10AGPR35KCNH2GRM5MALT1 | |
| SCHEMBL22205240 | 0.79 | PDK1 (0.48) | SCN10AGPR35KCNH2GRM5MALT1 | |
| SCHEMBL21605071 | 0.76 | KDM4E (0.47) | SCN10AJAK2JAK1CYP11B2LRRK2 | |
| SCHEMBL21605007 | 0.75 | EGLN2 (0.47) | SCN10AKCNH2GRM5MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034141-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-30 | — | — | US | disclosed |
| US-12152027-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-26 | — | — | US | disclosed |
| US-11897879-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-13 | — | — | US | disclosed |
| CN-116710089-A | Materials and methods for treating cancer | 莫诺泰罗斯疗法公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20220089595-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-24 | — | — | US | disclosed |
| US-20220048916-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-17 | — | — | US | disclosed |
| US-11230545-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20210332045-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-28 | — | — | US | disclosed |
| CN-113038948-A | Heterocyclic compounds | 武田药品工业株式会社 | 2021-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089595-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | SCN10A 1447/4885JAK2 3831/4885JAK1 3081/4885 |
| US-20250034141-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | SCN10A 1447/4885JAK2 3831/4885JAK1 3081/4885 |
| US-11230545-B2 | Heterocyclic compound | MALT1, SQSTM1, PPM1D | SCN10A 1447/4885JAK2 3831/4885JAK1 3081/4885 |
| US-20210332045-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | SCN10A 1447/4885JAK2 3831/4885JAK1 3081/4885 |
| US-12152027-B2 | Heterocyclic compound | MALT1, SQSTM1, PPM1D | SCN10A 1447/4885JAK2 3831/4885JAK1 3081/4885 |
| US-20220048916-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | SCN10A 1447/4885JAK2 3831/4885JAK1 3081/4885 |
| US-11897879-B2 | Heterocyclic compound | MALT1, SQSTM1, PPM1D | SCN10A 1447/4885JAK2 3831/4885JAK1 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.